Intra-Arterial Chemotherapy in Liver Metastatic Bladder Cancer Refractory to Standard Therapy: Two Case Reports

Intra-Arterial Chemotherapy in Metastatic Bladder Cancer Refractory to Standard Therapy: Two Case Reports. Int J Case Rep Ther Stud 1: 004. Abstract Bladder cancer is the commonest malignancy of the urinary tract. Unfortunately most patients develop metastases during the course of their medical history. In this setting, chemotherapy treatment re- mains the only therapeutic option. Today, there is not standard therapy over the second line chemotherapy. We reported our experience with intra-arterial chemotherapy in two patients with metastatic bladder cancer liver progression disease after standard chemotherapy. The schedule used consisted in epirubicin 35 mg/mq and cisplatin 42 mg/mq administered into hepatic artery proper by bolus injection through a catheter inserted in the femoral artery with the Seldinger method, with cycles repeated every 21 days. Intra-arterial chemotherapy provided a good liver disease control, allowing to treat disease progression with radiotherapy, without important adverse events. Interesting, intra-arterial che- motherapy was well tolerated despite age, previous treatment and related residual toxicities.